Reuters logo
BRIEF-Redhill Biopharma announces top-line results from bekinda® 12 mg phase ii study for IBS-D 
September 28, 2017 / 11:33 AM / 20 days ago

BRIEF-Redhill Biopharma announces top-line results from bekinda® 12 mg phase ii study for IBS-D 

Sept 28 (Reuters) - Redhill Biopharma Ltd

* Redhill Biopharma Ltd to announce top-line results from bekinda® 12 mg phase ii study for IBS-D on October 3rd, 2017

* Redhill Biopharma Ltd - ‍expects to announce top-line results from phase ii clinical study with bekinda on Tuesday, October 3 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below